Piper Sandler Downgrades Antares Pharma (ATRS) to Neutral

Piper Sandler analyst David Amsellem downgraded Antares Pharma (NASDAQ: ATRS) from Overweight to Neutral with a price target of $5.60 (from $6.00).

For an analyst ratings summary and ratings history on Antares Pharma click here. For more ratings news on Antares Pharma click here.

Shares of Antares Pharma closed at $5.58 yesterday.

You May Also Be Interested In

• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Beike (BEKE) PT Raised to $23 at Morgan Stanley
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics